Ionis Pharmaceuticals, Inc. (IONS)

Sage Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	297.3	242.08	399.27	276.47	869.19	397.66
Short-Term Investments	1,996	2,061	1,938	1,721	1,264	1,501
Cash & Short-Term Investments	2,293	2,303	2,338	1,997	2,133	1,899
Cash Growth	9.95%	-1.48%	17.03%	-6.37%	12.32%	-24.30%
Receivables	52.58	92.19	97.78	25.54	61.9	76.2
Inventory	8.48	12.51	7.44	22.03	24.81	21.97
Other Current Assets	223.12	212.67	199.13	157.72	125.17	133.42
Total Current Assets	2,577	2,620	2,642	2,203	2,345	2,131
Property, Plant & Equipment	275.88	256.11	242.94	255.84	196.04	181.08
Long-Term Investments	22.82	41.02	42.99	40.37	32.32	15.06
Other Intangible Assets	-	-	-	-	-	27.94
Other Long-Term Assets	109.28	86.26	62.29	34.97	38.28	34.97
Total Assets	2,985	3,004	2,990	2,534	2,612	2,390
Accounts Payable	22.8	42.96	26.03	17.92	11.9	17.2
Accrued Expenses	145.52	178.05	215.62	189.28	127.37	155.89
Current Portion of Long-Term Debt	652.92	0.22	45.07	0.32	0.9	316.11
Current Portion of Leases	-	9.06	8.09	7.22	2.63	-
Current Income Taxes Payable	0.08	0.03	2.15	6.25	0.04	1.32
Current Unearned Revenue	75.91	78.99	151.13	90.58	97.71	108.38
Total Current Liabilities	897.24	309.32	448.09	311.56	240.55	598.9
Long-Term Debt	1,167	1,788	1,743	1,183	1,228	623.53
Long-Term Leases	164.38	161.81	170.88	178.94	19.43	-
Long-Term Unearned Revenue	125.1	156.5	241.18	287.77	351.88	424.05
Total Liabilities	2,353	2,415	2,603	1,961	1,840	1,646
Common Stock	0.16	0.16	0.14	0.14	0.14	0.14
Additional Paid-In Capital	2,933	2,869	2,215	2,060	1,964	1,896
Retained Earnings	-2,273	-2,250	-1,796	-1,430	-1,160	-1,131
Comprehensive Income & Other	-27.99	-30.81	-32.65	-57.48	-32.67	-21.07
Total Common Equity	631.72	588.35	386.69	572.89	771.74	743.28
Shareholders' Equity	631.72	588.35	386.69	572.89	771.74	743.28
Total Liabilities & Equity	2,985	3,004	2,990	2,534	2,612	2,390
Total Debt	1,984	1,959	1,967	1,369	1,251	939.64
Net Cash (Debt)	308.97	344.14	370.23	628.21	882.13	959.48
Net Cash Growth	209.74%	-7.05%	-41.07%	-28.78%	-8.06%	-44.26%
Net Cash Per Share	1.98	2.30	2.59	4.43	6.26	6.87
Filing Date Shares Outstanding	159.39	158.96	145.75	142.95	141.69	140.86
Total Common Shares Outstanding	159.2	157.91	144.34	142.06	141.21	140.37
Working Capital	1,680	2,311	2,194	1,891	2,104	1,532
Book Value Per Share	3.97	3.73	2.68	4.03	5.47	5.30
Tangible Book Value	631.72	588.35	386.69	572.89	771.74	715.35
Tangible Book Value Per Share	3.97	3.73	2.68	4.03	5.47	5.10
Land	-	8.57	8.57	8.57	23.06	23.06
Buildings	-	41.23	41.23	41.16	144.05	137.88
Machinery	-	9.86	9.84	9.58	10.59	12.87
Leasehold Improvements	-	54.38	28.28	28.36	20.14	17.26

Updated Jul 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q